Immunomodulujące właściwości leków przeciwdrobnoustrojowych

• Autorzy: Pejsak Z. , Truszczynski M.

Warianty tytułu

EN

Immunomodulating properties of antimicrobial drugs

• Języki publikacji: PL

Abstrakty

EN

The purpose of this article is to present immunosuppressive and immunostimulating properties of antimicrobial drugs, particularly of antibiotics. Among the former, also known as the adverse effects of these substances on the immune response, the article discusses chemotaxis, lymphocyte transformation, delayed hypersensitivity, antibody production, phagocytosis and the microbial activity of phagocytes. The immunostimulatory effects of antimicrobial drugs, including antibiotics, can occasionally be therapeutically useful, at present in human medicine. In a general sense, immunomodulatory effects of antimicrobial drugs fall into the following categories: stimulation of the inflammatory response, inhibition of the anti-inflammatory response, and promotion of the anti-inflammatory response. The immunomodulatory effects of antibiotics have mainly been shown in vitro or in experiments with laboratory animals. Until now, there has been little evidence from clinical observations, particularly in relation to infectious diseases of domestic animals, that these modulatory actions of antibiotics play a significant role. As far as humans are concerned, the most convincing in this respect are the anti-inflammatory effects of macrolides and tetracyclines. Considering the importance of antibiotics that - in addition to their antimicrobial action - would also stimulate the innate and specific immunity in the control of bacterial diseases of animals, further research in this area is needed.

Słowa kluczowe

PL

leki; antybiotyki; chemioterapeutyki; wlasciwosci immunomodulujace; oddzialywanie na organizm

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2012
• Tom: 68
• Numer: 02
• Opis fizyczny: s.79-83,rys.,tab.,bibliogr.

Twórcy

autor

Pejsak Z.

• Zakład Chorób Świń, Państwowy Instytut Weterynaryjny - Państwowy Instytut Badawczy, Al.Partyzantów 57, 24-100 Puławy

autor

Truszczynski M.

Bibliografia

• 1.Anderson R. A.: The effect of antibiotics and drug associations including antibiotics on the immunodeficient, [w:] Useful and harmful interactions of antibiotics. Red. Neumann M., CRP Press, Inc. Boca Raton, Fla 1985, 185-203.
• 2.Arvilommi H., Vuori M., Salmi A.: Immunosuppression by cotrimoxazole. (Lester) Br. Med. J. 1972, 3, 761-762.
• 3.Arvilommi H., Vouri M., Salmi A.: Sulfamethxoxazole-trimethoprim: Effect on antibody response in man. Chemotherapy 1976, 22, 37-42.
• 4.Connolly M. J., Snow M. H., Ingram H. R.: Ciprofloxacin treatment of recurrent Salmonella typhimurium septicaemia in a patient with acquired immune deficiency syndrome. J. Antimicrob. Chemother. 1986, 18, 647-648.
• 5.Dallegri F., Dapino P., Arduino N., Bertoletto M., Ottonello L.: Cefoperazone prevents the inactivation of a 1-antitrypsin by activated neutrophils. Antimicrob. Agents Chemother. 1999, 43, 2301-2303.
• 6.Daniel T. M., Suhrland L. G., Weinberger A. S.: Suppression of the anamnestic response to tetanus toxoid in man by chloramphenicol. N. Engl. J. Med. 1965, 173, 367-369.
• 7.Douglas S. D.: Cells involved in immune responsem, [w:] Fudenberg H. H., Stites D. P., Caldwell J. L., Wells J. V. (eds.): Basic and clinical immunology. Los Altos, California: Lange Medical Publications 1980, 96-114.
• 8.Dzierżanowski D.: Antybiotyki w praktyce ambulatoryjnej. α-Medica Press, Bielsko-Biała 2004.
• 9.Esposito S., Gaeta G. B., Galati D., Barber D.: Successful treatment with ciprofloxacin of Salmonella typhimurium infection in an immunocompromised host. Infection 1985, 13, 288-290.
• 10.Gabler W. L., Creamer H. R.: Suppression of human neutrophil functions by tetracycline. J. Periodontal. Res. 1991, 26, 52-58.
• 11.Gabler W. L., Smith J., Tsukuda N.: Compoarison of doxycycline and a chemically modified tetracycline inhitition of leukocyte functions. Res. Commun. Chem. Pathol. Pharmacol. 1992, 78, 151-160.
• 12.Gajda A., Posyniak A.: Właściwości farmakologiczne azalidów - udoskonalonych antybiotyków makrolidowych. Medycyna Wet. 2010, 66, 453-458.
• 13.Goodhart G. L.: Effect of aminoglycosides on the chemotactic response of human polymorphonuclear leukocytem. Antimicrob. Agents Chemother 1977, 12, 540-542.
• 14.Guz K., Bugla-Płoskońska G.: Immunomodulacyjne i przeciwzapalne właściwości wybranych antybiotyków i chemioterapeutyków. Postępy Hig. Med. Dośw. 2007, 61, 828-837.
• 15.Hauser W. E., Remington J. S.: Effect of Antibiotics on the Immune Response. Am. J. Med. 1982, 72, 711-716.
• 16.Kettle A. J., Gedye C. A., Winterbourn C. C.: Superoxide i san antagonisto of anti-inflammatory drugs that inhibit hypochlorous acid production by myeloperoxidase. Biochem. Pharmacol. 1993, 45, 2003-2010.
• 17.Kuzin I. I., Synder J. E., Ugine G. D., Wu D., Lee S., Bushnell T. Jr., Intel R. A., Young F. M., Bottaro A.: Tetracyclines inhibit activated B cell function. Int. Immunol. 2001, 13, 921-931.
• 18.Labro M. T.: Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy tales"? Clin. Microbiol. Rev. 2000, 13, 615-650.
• 19.Mathy-Hartert M., Deby-Dupont G., Deby C., Jadoul L., Vandenberghe A., Lamy M.: Cytotoxicity towards human endothelial cells, induced by neutrophil myeloperoxidase: protection by ceftazidime. Mediators Inflamm. 1995, 4, 437-443.
• 20.McEwen S. A., Fredorka-Cray P. J.: Antimicrobial use and resistance in animals. Clin. Inf. Dis. 2002, 34, 93-106.
• 21.Meer J. W. M. van der: Immunomodulation by antimicrobial drugs. Neth. J. Med. 2003, 61, 233-234.
• 22.Metchnikoff E.: 1908 The Nobel Lecture. Reprintem in Scand. J. Immunol. 1989, 30, 385-398.
• 23.Morikawa K., Oseko F., Morikawa S.: Immunomodulatory effect of fosfomycin on human B-lymphocyte function. Antimicrob. Agents Chemother. 1993, 37, 270-275.
• 24.Morikawa K., Oseko F., Morikawa S., Iwanowo K.: Immunomodulatory effects of three macrolides, midecamycin acetale, josamycin, and clarithromycin, on human T-lymphocyte function in vitro. Antimicrob. Agensts Chemother. 1994, 38, 2643-2647.
• 25.Munoz J., Geister T.: Inhibition of phagocytosis by aureomycyn. Proc. Soc. Exp. Biol. Med. 1950, 75, 367-370.
• 26.Ottonello L., Dallegri F., Dapino P., Pastorino G., Sacchetti C.: Cytoprotection against neutrophil-delivered oxidant attaca by antibiotics. Biochem. Pharmacol. 1991, 42, 2317-2321.
• 27.Pasquale T. R., Tan J. S.: Nonantimicrobial effects of antibacterial agents. Clin. Infect. Dis. 2005, 40, 127-135.
• 28.Purswani M., Eckert S., Arora H., Johann-Liang R., Noel G. J.: The effect of three broad-spectrum antimicrobials on mononuclear cell responses to encapsulated bacteria: evidence for down-regulation of cytokine MRN transcription by trovafloxacin. J. Antimicrob. Chemother. 2000, 46, 921-929.
• 29.Riesbeck K., Forsgren A., Henriksson A., Bredberg A.: Ciprofloxacin induces an immunomodulatory stress response in human T lymphocytes. Antimicrob. Agents Chemother. 1998, 42, 1923-1930.
• 30.Sacha P. T., Zaremba M. L., Jakoniuk P.: The effect of selected antimicrobial antibiotics on production of interferon gamma (IFN-G) by Mouse T-lymphocytes stimulated by Listeria monocytogenes. Med. Doœw. Mikrobiol. 1999, 51, 413-419.
• 31.Saiman L., Marshall B. C., Mayer-Hamblett N., Burns J. L., Quittner A. L., Cibene D. A., Coquillette S., Fieberg A. Y., Accurso F. J., Campbell P. W.: III. Macrolide Study Group: Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003, 290, 1749-1756.
• 32.Schultz M. J.: Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis. J. Antimicrob. Chemother. 2004, 54, 21-28.
• 33.Seklecki M. M., Quintiliani R., Maderazo E. G.: Aminoglycoside antibiotics moderately impair granulocyte function. Antimicrob. Agents Chemother 1978, 13, 552-554.
• 34.Shalit I.: Immunological aspects of new quinolones. Eur. J. Clin. Microbiol. Infect. Dis. 1991, 10, 262-266.
• 35.Shapira L., Soskolne W. A., Houri Y., Barak V., Halabi A., Stabholz A.: Protection against endotoxic shock and lipopolysaccharide-induced local inflammation by tetracycline: correlation with inhibition of cytokinez secretin. Infect. Immun. 1996, 40, 825-828.
• 36.Smith-Norowitz T. A., Bluth M. H., Drew H., Norowitz K. B., Chice S., Shah V. N., Nowakowski M., Josephson A. S., Durkin H. G., Joks R.: Effect of minocycline and doxycycline on IgF responsem. Ann. Allergy Astma Immunl. 2002, 89, 172-179.
• 37.Tentori L., Graziani G., Porcelli S. A., Sugita M., Brenner M. B., Madaio R., Bonmassar E., Giuliani A., Aquino A.: Rifampin increases cytokinez-induced expression of the CD1b molecule in human peripheral blond monocytem. Antimicrob. Agents Chemother. 1998, 42, 550-554.
• 38.Truszczyński M., Pejsak Z.: Antybiotykooporność bakterii zoonotycznych występujących u zwierząt i w żywności. Życie Wet. 2010, 85, 891-894.
• 39.Truszczyński M., Pejsak Z.: Pasze lecznicze w zwalczaniu zakaźnych chorób świń. Życie Wet. 2011, 86, 350-353.
• 40.Williams J. D.: Non-antimicrobial activities of macrolides. Int. J. Antimicrob. Agents 2001, 18, S89-S91.
• 41.Yoneshima Y., Ichiyama T., Ayukawa H., Matsubara T., Furukawa S.: Fosfomycin inhibits NF-KB activation in U-937 and Jurkat cells. Int. J. Antimicrob. Agents 2003, 21, 589-592.
• 42.Zhang X., Li G., Feng H., Xiong H., Zhang L., Song Y., Yu L., Deng X.: Valnemulin downregulates nitric oxide, prostaglandyn E2, and cytokinez production via inhibition of NF-кB and MAPK activity. Int. Immunopharmacol. 2009, 9, 810-816.